50% (well, maybe 40%) is my estimate of % of Sovaldi starts that are GT1. This is US only, since that's what's going to be most relevant in 2014. Even if we assume tripling of GT2 treatment starts and Sovaldi getting 90% of them, GT1 is still going to remain a significant contributor. What is your estimate?